BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Business

  Xtant Medical Announces Third Quarter 2022 Financial Results

  Xtant Medical Holdings, Inc. reported financial and operating results for the third quarter ended September 30, 2022.

  November 3, 2022

   · 

  11 min read
• Business

  Cara Therapeutics Announces Appointment of Lisa von Moltke, M.D., to its Board of Directors

  Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the appointment of Lisa von Moltke, M.D., to its Board of Directors.

  November 3, 2022

   · 

  3 min read
• Business

  Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

  Quoin Pharmaceuticals Ltd., a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced updated timing for its third quarter 2022 business update conference call and webcast.

  November 3, 2022

   · 

  1 min read
• Pharm Country

  TELA Bio to Participate in Canaccord MedTech, Diagnostics and Digital Health & Services Forum

  TELA Bio, Inc. announced that the Company will participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum on November 17th, 2022.

  November 3, 2022

   · 

  1 min read
• Business

  Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

  Keros Therapeutics, Inc. provided a business update and reported financial results for the quarter ended September 30, 2022.

  November 3, 2022

   · 

  8 min read
• Drug Development

  Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting

  Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, presented a poster highlighting favorable AT-752 Phase 1 clinical data for the treatment of dengue fever at the American Society of Tropical Medicine & Hygiene 2022 Annual Meeting in Seattle, Washington.

  November 3, 2022

   · 

  7 min read
• Business

  IRADIMED CORPORATION Announces Third Quarter 2022 Financial Results

  IRADIMED CORPORATION announced its financial results for the three and nine months ended September 30, 2022.

  November 3, 2022

   · 

  15 min read
• BioMidwest

  Bio-Techne to Present at the Credit Suisse 31st Annual Healthcare Conference

  Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST.

  November 3, 2022

   · 

  2 min read
• Biotech Beach

  Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

  Ainos, Inc. announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha formulation, VELDONA®.

  November 3, 2022

   · 

  8 min read
• Biotech Beach

  ACELYRIN, INC. to Present at Upcoming Investor Conferences - November 03, 2022

  ACELYRIN, INC. announced that its Co-founder and Chief Executive Officer Shao-Lee Lin, MD, PhD will present at the following upcoming investor conferences:

  November 3, 2022

   · 

  1 min read